801233-40-9

Basic information

• Product Name: methyl (3,5-difluoro-4-methoxybenzoyl)acetate
• Synonyms: methyl (3,5-difluoro-4-methoxybenzoyl)acetate
• CAS NO: 801233-40-9
• Molecular Weight: 244.195
• Mol File: 801233-40-9.mol

Chemical Properties

• CAS DataBase Reference: methyl (3,5-difluoro-4-methoxybenzoyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (3,5-difluoro-4-methoxybenzoyl)acetate(801233-40-9)
• EPA Substance Registry System: methyl (3,5-difluoro-4-methoxybenzoyl)acetate(801233-40-9)

Safety Data

• Hazardous Substances Data: 801233-40-9(Hazardous Substances Data)

Upstream product

• 616-38-6 carbonic acid dimethyl ester 
• 170570-79-3 1-(3,5-difluoro-4-methoxy-phenyl)ethanone 

Downstream Products

• 801233-48-7 2-(3,5-difluoro-4-methoxyphenyl)-6-methoxyquinolin-4-ol 
• 801233-77-2 4-bromo-2-(3,5-difluoro-4-hydroxyphenyl)quinolin-6-ol 
• 801233-62-5 4-bromo-2-(3,5-difluoro-4-methoxyphenyl)-6-methoxyquinoline 

Relevant articles and documents

Fluorous l -Carbidopa Precursors: Highly Enantioselective Synthesis and Computational Prediction of Bioactivity

New fluorous enantiopure (S)-α-aminated β-keto esters were prepared through a highly enantioselective electrophilic α-amination step in the presence of europium triflate and (R,R)-phenyl-pybox. These compounds are precursors of fluorinated analogues of l-

ERβ ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives

A new class of estrogen receptor β (ERβ) ligands based on the 2-phenylquinoline scaffold was prepared. Several analogues with C4 substitution displayed high affinity (3-5 nM) and significant selectivity (up to 83-fold) for ERβ. The best compound, 13b, was profiled as a selective partial agonist for ERβ at 1 μM in a cell-based transcriptional assay. Uterine weight bioassay of 13b indicated no activation of ERα in vivo.

PHENYL GUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS

This invention provides estrogen receptor modulators of formula: (I), having the structure wherein, R1, R2, R3, R4, R5 and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.